tiprankstipranks
Trending News
More News >
MaaT Pharma (FR:MAAT)
:MAAT
France Market
Advertisement

MaaT Pharma (MAAT) AI Stock Analysis

Compare
3 Followers

Top Page

FR:MAAT

MaaT Pharma

(MAAT)

Rating:47Neutral
Price Target:
€5.50
▼(-6.78% Downside)
MaaT Pharma's overall stock score is primarily impacted by its financial performance, which reflects ongoing losses and high leverage typical of biotech firms. Technical analysis provides some positive momentum, but valuation remains a significant concern due to negative earnings and lack of dividends. The absence of earnings call data and corporate events limits further insights.
Positive Factors
Clinical Trial Success
The pivotal ARES P3 study exceeded expectations with a 62% GI-ORR at day 28, well above the anticipated 38%.
Financial Strength
The company announced a €13m private placement, providing visibility into 4Q25, giving room to breathe until upcoming inflection points.
Regulatory Progress
MaaT013 is about to secure its first regulatory approval, and MaaT033 has demonstrated its excellent safety in both post allo-HSCT and ALS.
Negative Factors
Funding Challenges
The pressing issue is to secure additional funding, as the company's cash position only extends to the second quarter of 2025.
Investment Risks
Risks to the investment thesis include failure of clinical trials, regulatory requirements for additional studies, and the potential need to raise additional funds under poor market conditions.

MaaT Pharma (MAAT) vs. iShares MSCI France ETF (EWQ)

MaaT Pharma Business Overview & Revenue Model

Company DescriptionMaaT Pharma (MAAT) is a biopharmaceutical company specializing in the development of microbiome-based therapies. The company operates in the healthcare sector, focusing on restoring the balance of gut microbiota to treat various diseases, particularly in the fields of oncology and hematology. MaaT Pharma's core products include a pipeline of proprietary biotherapeutics designed to improve patient outcomes through microbiota restoration.
How the Company Makes MoneyMaaT Pharma makes money primarily through the development and commercialization of its microbiome-based therapeutics. The company generates revenue from licensing agreements, research collaborations, and milestone payments with pharmaceutical companies and research institutions. Additionally, MaaT Pharma may earn income from grants and funding related to its research and development activities. Key partnerships with academic and commercial entities contribute to its earnings by facilitating the advancement and potential market introduction of its therapeutic products.

MaaT Pharma Financial Statement Overview

Summary
MaaT Pharma is experiencing financial difficulties typical of biotech firms, with ongoing losses and high leverage. Despite revenue growth, the company faces significant operating losses and negative cash flows. The balance sheet shows high debt levels, and cash flow issues are evident, indicating a need for improved financial stability.
Income Statement
45
Neutral
MaaT Pharma has shown revenue growth over the years, with a 44.36% increase from 2023 to 2024. However, the company is still operating at a loss, with a negative net profit margin of -898.45% in 2024. The gross profit margin in 2024 was 61.13%, indicating some efficiency in covering the cost of goods sold. EBIT and EBITDA margins remain negative, reflecting significant operating losses.
Balance Sheet
35
Negative
The company's balance sheet reveals a high debt-to-equity ratio of 1.54 in 2024, suggesting high leverage. The equity ratio decreased to 26.84%, indicating a decline in equity relative to total assets. Return on equity remains negative due to continued net losses, highlighting profitability challenges.
Cash Flow
40
Negative
Operating cash flow is negative and worsening, with a free cash flow of -22.79 million in 2024. The operating cash flow to net income ratio is 0.76, indicating cash flow issues in supporting net losses. The free cash flow to net income ratio is 0.79, suggesting limited free cash available relative to net losses.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.22M2.23M1.43M972.00K0.00
Gross Profit1.97M1.66M1.09M806.00K-164.00K
EBITDA-26.34M-19.74M-13.31M-8.71M-6.58M
Net Income-28.90M-19.72M-13.87M-9.14M-5.35M
Balance Sheet
Total Assets38.50M42.93M44.73M49.42M24.28M
Cash, Cash Equivalents and Short-Term Investments20.22M24.31M35.31M43.30M19.91M
Total Debt15.96M14.07M11.36M5.81M6.08M
Total Liabilities28.16M22.46M17.91M9.56M8.34M
Stockholders Equity10.34M20.47M26.81M39.86M15.94M
Cash Flow
Free Cash Flow-22.79M-19.76M-13.27M-8.17M-6.13M
Operating Cash Flow-22.04M-18.67M-12.61M-7.93M-5.81M
Investing Cash Flow-416.00K-440.00K-815.00K-238.00K-523.00K
Financing Cash Flow18.33M8.14M5.36M31.56M20.84M

MaaT Pharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.90
Price Trends
50DMA
5.08
Positive
100DMA
5.32
Positive
200DMA
6.36
Negative
Market Momentum
MACD
0.18
Negative
RSI
59.72
Neutral
STOCH
58.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:MAAT, the sentiment is Positive. The current price of 5.9 is above the 20-day moving average (MA) of 5.38, above the 50-day MA of 5.08, and below the 200-day MA of 6.36, indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 59.72 is Neutral, neither overbought nor oversold. The STOCH value of 58.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:MAAT.

MaaT Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$183.12M-48.02%
52
Neutral
€62.64M-57.56%-1.92%-9.26%
51
Neutral
$7.73B-0.08-44.86%2.23%22.72%-1.44%
49
Neutral
€103.70M-49.28%55.02%
47
Neutral
€90.21M
44.34%-27.37%
44
Neutral
€135.04M-220.48%-97.04%-32.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:MAAT
MaaT Pharma
5.90
-1.10
-15.71%
FR:TNG
Transgene
1.03
0.01
0.98%
FR:ABNX
ABIONYX Pharma SA
1.88
0.59
45.74%
FR:ALCLS
Cellectis SA
2.65
0.66
33.12%
FR:ALSEN
Sensorion SAS
0.35
-0.34
-48.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025